Get the Stockscreener App
6.97
3.72%
0.25
After Hours:
6.98
0.01
+0.14%
Athira Pharma Inc stock is traded at $6.97, with a volume of 1.39M.
It is up +3.72% in the last 24 hours and up +46.43% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$6.72
Open:
$6.71
24h Volume:
1.39M
Relative Volume:
1.44
Market Cap:
$27.49M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-2.2557
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
+80.10%
1M Performance:
+46.43%
6M Performance:
+2,148%
1Y Performance:
+1,172%
1-Day Range:
$6.37
$7.25
1-Week Range:
$3.8001
$8.36
52-Week Range:
$0.2195
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
6.97 | 26.50M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Why retail investors favor Athira Pharma Inc. stockQuarterly Portfolio Review & Consistent Return Investment Signals - ulpravda.ru
How strong is Athira Pharma Inc. stock balance sheetMarket Sentiment Report & Weekly High Return Stock Opportunities - Bölüm Sonu Canavarı
Can Athira Pharma Inc. stock beat analyst upgradesTrade Signal Summary & Precise Buy Zone Identification - ulpravda.ru
Does Athira Pharma Inc. stock trade at a discount to peersJuly 2025 Big Picture & Daily Volume Surge Signals - ulpravda.ru
Volume Summary: Why retail investors favor Athira Pharma Inc. stockJuly 2025 Technicals & AI Powered Market Entry Ideas - ulpravda.ru
Mizuho maintains Neutral on Athira Pharma stock after transformative deals By Investing.com - Investing.com Canada
How analysts rate Athira Pharma Inc. stock todayTrade Risk Report & Daily Momentum Trading Reports - Bölüm Sonu Canavarı
Will Athira Pharma Inc. stock benefit from automationWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It - Citeline News & Insights
Athira Pharma, Inc. (ATHA) Stock: Rockets 68% After Phase 3 Lasofoxifene Deal and $90M Private Placement - parameter.io
Athira Pharma Inc.: Growth or Bubble? - StocksToTrade
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - GeekWire
Athira Pharma stock shot up 60% today – what’s triggering the super rally? - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Athira Pharma, Inc. announced that it expects to receive $90 million in funding - marketscreener.com
Athira Pharma announces license to develop, commercialize lasofoxifene - TipRanks
Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal - Blockonomi
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Asianet Newsable
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com Nigeria
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug By Investing.com - Investing.com South Africa
Is It Too Late to Buy Athira Pharma Inc. Stock? - timothysykes.com
Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks
Athira Pharma pivots to oncology with new licensing deal - TipRanks
Athira Pharma acquires rights to phase 3 breast cancer drug - Investing.com
Athira Pharma Signs Multiple Material Agreements - TradingView — Track All Markets
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewswire
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Can Athira Pharma Inc. stock sustain market leadership2025 Bull vs Bear & Verified Momentum Stock Ideas - ulpravda.ru
Contrasting Day One Biopharmaceuticals (NASDAQ:DAWN) & Athira Pharma (NASDAQ:ATHA) - Defense World
Entry Recap: Will Athira Pharma Inc stock outperform growth indexesJuly 2025 Update & Free Risk Controlled Daily Trade Plans - moha.gov.vn
How Athira Pharma Inc. stock trades before earningsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Will Athira Pharma Inc. stock outperform growth indexes2025 Market Overview & Accurate Buy Signal Alerts - Newser
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
What analysts say about Athira Pharma Inc stockIndustrial Stocks Review & Start Learning With Our Courses - earlytimes.in
Why Athira Pharma Inc. stock could benefit from AI revolutionJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Athira Pharma Inc. stock performs during Fed tightening cycles2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Athira Pharma Inc. stock outlook for YEARGap Up & Weekly Market Pulse Updates - newser.com
Why Athira Pharma Inc. stock is popular among millennialsEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
How to escape a deep drawdown in Athira Pharma Inc.Earnings Growth Summary & Consistent Return Strategy Ideas - newser.com
What makes Athira Pharma Inc. stock attractive to growth fundsJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Will Athira Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Top chart patterns to watch in Athira Pharma Inc.July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):